PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Jackson, Evangeline R., Kearney, Padraic S., Jamaluddin, M. Fairuz B., Douglas, Alicia M., Beitaki, Tyrone, McEwen, Holly P., Persson, Mika L., Hocke, Emily A., Jain, Vaibhav, Aksu, Michael, Manning, Elizabeth E., Parackal, Sarah G., Murray, Heather C., Verrills, Nicole M., Hua, Susan, Cairns, Murray J., Alvaro, Frank, Dayas, Christopher V., Dun, Matthew D., Hua, S, de Bock, CE, Colino-Sanguino, Y, Kiltschewskij, Dylan, Valdes-Mora, F, Tsoli, M, Ziegler, DS, Cairns, MJ, Raabe, EH, Vitanza, NA, Hulleman, E, Phoenix, TN, Koschmann, C, Alvaro, F, Findlay, Izac J., Dayas, CV, Tinkle, CL, Wheeler, H, Whittle, JR, Eisenstat, DD, Firestein, R, Mueller, S, Valvi, S, Hansford, JR, Ashley, DM, Mannan, Abdul, Gregory, SG, Kilburn, LB, Nazarian, J, Cain, JE, Dun, MD, Staudt, Dilana E., Thomas, Bryce C., Germon, Zacary P., Laternser, Sandra

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

- Germon, Zacary P., Sillar, Jonathan R., McLachlan, Tabitha, Schjenken, John E., Skerrett-Byrne, David A., Huang, Honggang, Melo-Braga, Marcella N., Plank, Maximillan W., Alvaro, Frank, Chamberlain, Janis, De Iuliis, Geoff, Aitken, R. John, Mannan, Abdul, Nixon, Brett, Wei, AH, Enjeti, Anoop K., Huang, Y, Lock, RB, Larsen, MR, Lee, Heather, Vaghjiani, V, Cain, JE, de Bock, CE, Duchatel, Ryan J., Verrills, Nicole M., Dun, Matthew D., Staudt, Dilana, Murray, Heather C., Findlay, Izac J., Jackson, Evangeline R., McEwen, Holly P., Douglas, Alicia M.

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

- Venneti, Sriram, Kawakibi, Abed Rahman, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y., Arrillaga-Romany, Isabel, Batchelor, Tracy T., Butowski, Nicholas A., Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A., de Groot, John, Ji, Sunjong, Mehta, M, Hall, MD, Daghistani, D, Cloughesy, TF, Ellingson, BM, Beccaria, K, Varlet, P, Kim, MM, Umemura, Y, Garton, H, Waszak, Sebastian M., Franson, A, Schwartz, J, Jain, R, Kachman, M, Baum, H, Burant, CF, Mottl, SL, Cartaxo, RT, John, V, Messinger, D, Sweha, StefanR, Qin, T, Peterson, E, Sajjakulnukit, P, Ravi, K, Waugh, A, Walling, D, Ding, Y, Xia, Z, Schwendeman, A, Hawes, D, Mota, Mateus, Yang, F, Judkins, AR, Wahl, D, Lyssiotis, CA, de la Nava, D, Alonso, MM, Eze, A, Spitzer, J, Schmidt, SV, Duchatel, Ryan J., Pun, Matthew, Dun, Matthew D., Cain, JE, Jiang, L, Stopka, SA, Baquer, G, Regan, MS, Filbin, MG, Agar, NYR, Zhao, L, Kumar-Sinha, C, Deogharkar, Akash, Mody, R, Chinnaiyan, A, Kurokawa, R, Pratt, D, Yadav, VN, Grill, J, Kline, C, Mueller, S, Resnick, A, Nazarian, J, Chung, Chan, Allen, JE, Odia, Y, Gardner, SL, Koschmann, C, Tarapore, Rohinton S.

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities

- Sun, Claire Xin, Daniel, Paul, Adjumain, Shazia, Sun, Christie, Chong, Wai Chin, Fernando, Dasun, Drinkwater, Caroline, Tourchi, Motahhareh, Habarakada, Dilru, Sooraj, Dhanya, Carvalho, Diana, Storm, Phillip B., Bradshaw, Gabrielle, Baubet, Valerie, Sayles, LC, Fernandez, E, Nguyen, T, Pörksen, M, Doan, A, Crombie, DE, Panday, M, Zhukova, N, Dun, Matthew D., Shi, Hui, Ludlow, LE, Day, B, Stringer, BW, Neeman, N, Rubens, JA, Raabe, EH, Vinci, M, Tyrrell, V, Fletcher, JI, Ekert, PG, Loi, Melissa, Dumevska, B, Ziegler, DS, Tsoli, M, Syed Sulaiman, NF, Loh, AHP, Low, SYY, Sweet-Cordero, EA, Monje, M, Resnick, A, Jones, C, Chew, Nicole, Downie, P, Williams, B, Rosenbluh, J, Gough, D, Cain, JE, Firestein, R, Parackal, Sarah, Tsui, Vanessa, Liang, Yuqing, Koptyra, Mateusz

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

- Jackson, Evangeline R., Duchatel, Ryan J., Le Grand, Marion, Kearney, Padraic S., Douglas, Alicia M., Findlay, Izac J., Germon, Zacary P., McEwen, Holly P., Beitaki, Tyrone S., Patabendige, Adjanie, Skerrett-Byrne, David A., Nixon, Brett, Staudt, Dilana E., Smith, Nathan D., Day, B, Manoharan, N, Nagabushan, S, Hansford, JR, Govender, D, McCowage, GB, Firestein, R, Howlett, M, Endersby, R, Persson, Mika L., Gottardo, NG, Alvaro, F, Waszak, SM, Larsen, MR, Colino-Sanguino, Y, Valdés-Mora, F, Rakotomalala, A, Meignan, S, Pasquier, E, Andre, N, Mannan, Abdul, Hulleman, E, Eisenstat, DD, Vitanza, NA, Nazarian, J, Koschmann, C, Mueller, S, Cain, JE, Dun, MD, Yadavilli, Sridevi, Parackal, Sarah, Game, Shaye, Chong, Wai Chin, Jayasekara, W. Samantha N.

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

- Przystal, Justyna M., Cosentino, Chiara Cianciolo, Biery, Matt C., Myers, Carrie, Olson, James M., Panditharatna, Eshini, Kritzer, Bettina, Mourabit, Sulayaman, Vitanza, Nicholas A., Filbin, Mariella G., de Iuliis, Geoffry N., Dun, Matthew D., Yadavilli, Sridevi, Koschmann, C, Cain, JE, Grotzer, MA, Waszak, SM, Mueller, S, Nazarian, J, Zhang, Jie, Laternser, Sandra, Bonner, Erin R., Prasad, Rachna, Dawood, Adam A., Lobeto, Nina, Chong, Wai Chin